CMV IgG Positive and Kidney Donation: Risk Assessment and Management

CMV IgG+ = past CMV infection (latent virus). Common: 50–80% adults seropositive. In kidney transplantation, serostatus matching affects post-transplant CMV disease risk.

Donor/Recipient Risk Matrix

DonorRecipientRisk LevelKey Concern
IgG+IgG–Highest (D+/R–)Primary CMV infection in immunocompromised host → tissue-invasive disease, rejection risk, mortality
IgG+IgG+Moderate (D+/R+)Reactivation or reinfection; usually milder
IgG–IgG+Low (D–/R+)Recipient reactivation only
IgG–IgG–Lowest (D–/R–)No CMV exposure source

Does IgG+ Disqualify Donation?

No. CMV IgG+ donors are routinely accepted. Risk is managed, not avoided.

Mitigation Strategies

  • Prophylaxis: Valganciclovir 900mg daily × 3–6 months (D+/R– standard).
  • Preemptive therapy: Weekly CMV PCR monitoring; treat at threshold (e.g., >1000 IU/mL).
  • Antiviral prophylaxis also reduces other herpesviruses (HSV, VZV, EBV).
  • Enhanced monitoring for D+/R–: viral load, renal function, drug levels (valganciclovir myelosuppression).

Outcomes

  • Modern prophylaxis → CMV disease <10% in D+/R–.
  • Graft survival equivalent to matched pairs at 5 years.
  • Donor IgG+ status alone does not reduce graft/patient survival.

Discuss your specific serostatus pairing with transplant team. Protocols vary by center.

Kidney Disease - Related Articles